Arbutus Biopharma Corp Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Arbutus Biopharma Corp (ABUS) had Restructuring and Related Cost, Number of Positions Eliminated, Period Percent of 0.4 Rate as of 2024-08-01, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent · last filed 2025-03-27
- 2023-11-30: Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 1 month 24.00%.
pure
| Period end | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 1 month |
|---|---|
| 2023-11-30 | 24.00% 10-K · filed 2024-03-05 |
Rate
| Period end | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent |
|---|---|
| 2024-08-01 | 0.40 Rate 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |